1. Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study
Papademetriou et al. Am J Nephrol 2017;45:   (DOI: / )
Table 1. Baseline characteristics of study participants according to baseline CKD status

2. Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study
Papademetriou et al. Am J Nephrol 2017;45:   (DOI: / )
Table 1 (continued). Baseline characteristics of study participants according to baseline CKD status

3. Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study
Papademetriou et al. Am J Nephrol 2017;45:   (DOI: / )
Table 2. Baseline characteristics of study participants by baseline CKD status and treatment arm

4. Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study
Papademetriou et al. Am J Nephrol 2017;45:   (DOI: / )
Table 2 (continued). Baseline characteristics of study participants by baseline CKD status and treatment arm

5. Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study
Papademetriou et al. Am J Nephrol 2017;45:   (DOI: / )
Fig. 1. Lipid values with standard and intensive lipid therapy in CKD and non-CKD study participants. a Total cholesterol levels over time by baseline CKD status and lipid arm. b Triglyceride levels over time by baseline CKD status and lipid arm. c LDL-C levels over time by baseline CKD status and lipid arm. d HDL-C levels over time by baseline CKD status and lipid arm.

6. Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study
Papademetriou et al. Am J Nephrol 2017;45:   (DOI: / )
Fig. 2. Rates of primary and secondary outcomes according to CKD status at baseline among participants in the lipid arm of the ACCORD study.

7. Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study
Papademetriou et al. Am J Nephrol 2017;45:   (DOI: / )
Fig. 3. Rates for the primary and secondary outcomes by treatment group (intensive vs. standard) in patients with CKD (a) and without CKD (b) at baseline.

8. Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study
Papademetriou et al. Am J Nephrol 2017;45:   (DOI: / )
Table 3. Adverse events by treatment group and CKD status